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Novel vaginal delivery systems for local therapy as well as systemic administration
of peptides and proteins have been extensively investigated over the last decade. Ad-
vantages of the vaginal route of drug administration include: avoidance of hepatic first
pass metabolism, a reduction in the incidence and severity of gastrointestinal and/or he-
patic side effects, easiness of application and complete privacy of the therapy for women.
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The aim of our study was to develop a liposomal carrier
system for the local treatment of bacterial vaginosis, ca-
pable to efficiently deliver entrapped drug during an ex-
tended period of time. Chloramphenicol was entrapped
in liposomes composed of egg phosphatidylcholine/egg
phosphatidylgycerol-sodium (9:1, molar ratio) and pre-
pared by two different methods, the proliposome method
and the polyol dilution method. Both liposome prepara-
tions were characterised and compared for particle size,
polydispersity, entrapment efficiency and tested for in
vitro stability in media that simulate human vaginal con-
ditions (buffer pH 4.5 and vaginal fluid simulant). To
achieve application viscosity of liposomes and to further
improve their stability, liposomes prepared by the proli-
posome method were incorporated in the bioadhesive
gel made of Carbopol 974P NF resin. In vitro release stu-
dies of liposomes incorporated in the gel have shown a
prolonged release of entrapped chloramphenicol com-
pared to control gel. Even after 24 hours of incubation in
the vaginal fluid simulant, more than 40% of the origi-
nally entrapped drug was still retained in the gel. Storage
stability studies have proven the ability of the Carbopol
974P NF gel to preserve the original size distribution of
incorporated liposomes.
All the performed experiments confirm the applicability
of liposomes as a novel drug carrier system for the local
treatment of bacterial vaginosis.
Keywords: liposomes, chloramphenicol, bioadhesive gel,
stability, vaginal application
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However, the currently available vaginal drug delivery systems (e.g., foams, creams, gels
and tablets) have some limitations, such as leakage, messiness and low residence time,
which contribute to poor subject or patient compliance. Furthermore, intravaginal route
of drug administration may lead to a systemic rather than a localised effect due to the re-
markable absorption of the drug from the vaginal wall (1, 2). For that reason, attempts
are being made to develop novel vaginal drug delivery systems that can provide pro-
longed and/or controlled release of drugs.
Liposomes are well established as drug carriers in topical treatment of diseases, es-
pecially in dermatology. They can enhance penetration of encapsulated hydrophilic drugs
into the skin to enable a proper therapeutic effect (3). Because of their ability to provide
sustained release of the incorporated drug, liposomes also have the potential to be ap-
plied vaginally (4, 5).
One of the most common infectious gynaecological diseases is bacterial vaginosis. It
is a major cause of vaginitis, which is characterised by replacement of normal lactobacilli-
-dominated microflora with a mixed flora containing Gardnerella vaginalis, anaerobic bac-
teria and Mycoplasma hominis (6). Since bacterial vaginosis is a localised syndrome with
no apparent inflammation of the vaginal epithelium, topical antimicrobial treatment
provides an acceptable alternative to the systemic use (7). Local therapy of vaginitis gene-
rally includes administration of antibiotics and/or antifungal agents. The antibiotic
chloramphenicol (CHL) is commercially available as a cream for local therapy, but only
in dermatology and ophthalmology (8). Due to the broad spectrum of activity of the
drug against Gram-positive as well as Gram-negative bacteria, it is reasonable to con-
sider CHL application for the local vaginal treatment.
Previous studies have proven that application of liposomes containing CHL is pos-
sible in gynaecology (5). Continuing that research, here we report the development of a
bioadhesive liposomal gel containing CHL for the local therapy of bacterial vaginosis.
Liposomes composed of egg phosphatidylcholine (EPC) and egg phosphatidylglycerol-
-sodium (EPG) in the molar ratio 9:1 were prepared by the proliposome and the polyol
dilution methods and incorporated in the bioadhesive gel. To be closer to the actual in




Egg phosphatidylcholine (EPC), egg phosphatidylglycerol-sodium (EPG) and Car-
bopol 974P NF were generous gifts from Lipoid GmbH (Germany) and BFGoodrich (Bel-
gium), respectively. Chloramphenicol, bovine serum albumin and lactic acid were pur-
chased from Sigma Chemicals (Germany).
Phosphate buffer, pH 7.4, was composed of 137 mmol L–1 NaCl, 1.4 mmol L–1 KH2PO4
and 16.7 mmol L–1 Na2HPO4. Phosphate buffer, pH 4.5 was made of 100 mmol L–1 KH2PO4
in demineralised water.
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Vaginal fluid simulant (VFS) was prepared from 60 mmol L–1 NaCl, 25 mmol L–1
KOH, 3 mmol L–1 Ca(OH)2, 22.2 mmol L–1 lactic acid, 16.7 mmol L–1 acetic acid, 1.7
mmol L–1 glycerol, 6.7 mmol L–1 urea, 27.8 mmol L–1 glucose. Bovine serum albumin
was added in a concentration of 0.018 g L–1. pH of the mixture was adjusted to 4.5 using
0.1 mol L–1 HCl (2).
All chemicals used in the experiments were of analytical grade.
Preparation of liposomes
Liposomes containing CHL were prepared by two methods, the proliposome meth-
od (9) and the polyol dilution method (10). Concentrations of lipids as well as of the
drug were the same for each preparation and were of 26 mmol L–1 (total lipid) or 15
mmol L–1 (CHL), respectively.
Proliposome method. – EPC (180 mg), EPG (20 mg), CHL (50 mg) were mixed with
warm ethanol (160 mg) and the phosphate buffer pH 7.4 (400 mg) to achieve an initial
proliposome mixture. The mixture was stirred for 2 minutes at 60 °C, cooled to room
temperature and then converted to a liposome suspension by dropwise addition of 10
mL of the buffer, pH 7.4. During the last stage of this procedure, the suspension was
stirred continuously (600 rpm) for 60 minutes.
Polyol dilution method. – EPC and EPG (molar ratio 9:1) and CHL were dissolved in
propylene glycol (500 mg) at 60 C, and 500 mg of phosphate buffer, pH 7.4 (previously
warmed to the same temperature) was poured into the lipid-drug-polyol solution. The
suspension was diluted by the addition of a buffer, pH 7.4 (10 mL) under continuous
stirring (600 rpm) at 60 °C for 45 minutes and then cooled to room temperature.
Finally, both liposome suspensions were extruded three times through 0.4-m poly-
carbonate membrane filters (LiposoFast, Canada).
Lipid concentration was determined by quantification of inorganic phosphate using
the method of Bartlett (11).
Entrapment efficiency determination
Unentrapped (free) CHL was separated from liposomal CHL by gel chromatogra-
phy on the Sepharose CL 4B (Pharmacia, Sweden) column using a phosphate buffer, pH
7.4, for elution. The concentration of the drug (both in liposomes and free) was deter-
mined in all collected fractions spectrophotometrically ( = 276 nm) (5).
The recovery of CHL for all preparations was between 90.1–97.9% of the total amo-
unt involved in the procedure of liposomes preparation.
Size measurements
Morphology, size distribution and mean diameters of the liposomes were deter-
mined by image analysis microscopy (12). Morphology and size distribution of vesicles
(based on the number of particles) were determined using an Olympus BH-2 microscope
equipped with a computer-controlled image analysis system (Optomax V, Ai Cambridge
Ltd., UK). A microscopic field was scanned with a video camera and was digitised or
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broken into electronically defined individual picture elements. A representative sample
of approximately 10000 liposomes was measured.
Also, the mean diameter, as well as the polydispersity index and zeta potential of
the liposomes were determined by photon correlation spectroscopy, PCS (Zetamaster,
Malvern Instruments, UK) 24 hours after their preparation (13).
Gel preparation
As a vehicle for incorporation of liposomes for vaginal delivery, a bioadhesive gel
was made (13). Carbopol 974P NF (1 g) was dispersed in demineralised water (88 g) by
stirring at 800 rpm for 60 minutes. Then, propylene glycol (10 g) was added and the mix-
ture was neutralised by dropwise addition of 10% NaOH. Mixing was continued until a
transparent gel appeared, while the amount of the base was adjusted to achieve a gel
with pH 5.5.
Incorporation of liposomes into the gel
A previously described procedure (13) was applied. Liposomes containing CHL (se-
parated from the unentrapped drug) were mixed into the 1% (m/m) Carbopol gel with
an electrical mixer (25 rpm, 2 min), the concentration of liposomes in the gel being 10%
(m/m, liposome suspension/total). Control gels (10%, m/m) were made under the same
conditions. Instead of liposomes, those samples contained free CHL.
In vitro stability studies
Liposome preparations (both suspensions and gels) were tested for in vitro stability
in the phosphate buffer, pH 4.5. To be closer to human conditions, the same experiments
were performed in the vaginal fluid simulant (VFS), pH 4.5.
Liposome suspensions. – The method reported by Paveli} et al. (5) was used. Liposo-
mes (1 mL), separated from unentrapped CHL, were dispersed in the buffer, pH 4.5 (5
mL), and incubated at 37 °C using a water bath. Samples were taken at certain time in-
tervals (1, 2, 4, 6 and 24 hours), separated from the released drug and the amount of the
drug was determined spectrophotometrically (as described earlier).
Liposomal gels. – The procedure modified by Peschka et al. (14) was applied. Samples
of gel containing liposomal CHL (3 g) were put in glass vials and were separated from
the receptor solution (phosphate buffer, pH 4.5 or VFS) by a layer of 2% agarose gel. The
vials were incubated at 37 °C and the receptor solution was completely removed at cer-
tain time intervals (1, 2, 4, 6 and 24 hours). The amount of the released drug was deter-
mined spectrophotometrically before and after the addition of methanol.
Control experiments (Carbopol gels with free CHL) were done simultaneously and
under the same conditions.
Storage stability study
Samples of gel with liposomes containing CHL were stored at 20 and 40 °C for 4
weeks. The physical stability of the incorporated liposomes was determined by image
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analysis microscopy (as described above). In all experiments, approximately 5000 lipo-
somes were examined.
RESULTS AND DISCUSSION
Several novel carrier systems were suggested to be appropriate for vaginal drug de-
livery, such as polycarbophilic gel (15, 16), bioadhesive tablets (6), microspheres (17) and
liposomes (4, 5, 18). To achieve the desirable therapeutic effect of liposomes as drug car-
riers, they must be loaded with a sufficient amount of active compound. Therefore,
liposomes with CHL were prepared by two methods and compared for entrapment effi-
ciency, vesicle size and polydispersity (Table I). Regardless of the preparation procedure
used, liposomes were of a mean diameter between 310–330 nm. There was no statisti-
cally significant difference (t-test, p  0.05) between average diameters of liposomes esti-
mated by different measuring technique, image analysis and PCS, or between prolipo-
somes and PD liposomes. However, liposomes prepared by the polyol dilution method
(PD liposomes) were of a more homogenous size distribution than liposomes prepared
by the proliposome method (proliposomes). This was probably a consequence of the
preparation procedure; in the better case, the proliposome mixture was converted to a
stable liposome dispersion by dilution of the excess aqueous phase (9). Even after the
extrusion was performed through 400-nm pore size polycarbonate membranes, a small
amount of residual proliposome mixture remained in the final liposome dispersion, af-
fecting the polydispersity index (0.198) in comparison to the polyol dilution liposomes
(0.170). Since the same lipid composition was used for the preparation of liposomes, the
zeta potential values were quite similar for both preparations (about –55 mV). Con-
sidering the entrapment of CHL, a marginally better entrapment of the drug was ob-
tained in PD liposomes (30%) than in proliposomes (25%). Similar values obtained in the
previous study, where liposomes were composed of EPC only (5), indicate that the sur-
face charge of vesicles has no influence on the entrapment of CHL.
The next step in the investigation was to determine the in vitro stability of liposome
dispersions with CHL in media that mimic human vaginal conditions. Since normal va-
ginal pH of healthy women is usually between pH 4.0 and 5.0 (19), experiments were
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Table I. Characterisation of liposomes containing CHL






Polydispersity index 0.198 ± 0.029 0.170 ± 0.023
Zeta potential (mV) –54.2 ± 0.8 –55.1 ± 0.6
Entrapment efficiency (%) 24.8 ± 3.1 30.2 ± 4.1
The values denote the mean ± SD (n = 3).
a Determined by image analysis microscopy.
b Determined by PCS.
performed in the buffer of pH 4.5. As can be seen in Fig. 1, liposomes were stable in the
buffer of pH 7.4 (control). In the presence of a low pH, liposomes were less stable. After
1 hour of incubation at 37 °C, PD liposomes released almost 43% of the originally en-
trapped drug. During the following hours of testing, the release rate was much slower
and after 24 hours about 30% of the drug was still present in PD liposomes. Similar be-
haviour was observed when proliposomes were incubated at the buffer pH 4.5; fast re-
lease of the drug in the first 60 minutes and a slower release during the following 23
hours. Comparison of the two preparation methods has shown proliposomes to be more
stable; after 24 hours of incubation at pH 4.5 about 40% of originally entrapped CHL
was retained in the liposomes (Fig. 1). Relatively fast release of the entrapped CHL from
liposomes at pH 4.5 is probably a consequence of the pKa value of the drug (20). Further
investigations into the interaction of the CHL with membrane bilayer would be valuable
to explain the lower association rate of the CHL than expected for lipophilic drugs.
In previous experiments performed with hydrophilic model substances of different
molecular mass: calcein, Mr 622.5 (13), FITC-dextran, Mr 4400, and FITC-dextran, Mr
21200 (21), at the buffer pH 4.5, liposomes prepared by both methods could retain a
higher amount of originally entrapped marker (e.g., more than 60% calcein or even more
than 80% FITC-dextran 21200 remained in PD liposomes after 24 hours). Comparison of
those findings with the results obtained with CHL, demonstrate a slower release of wa-
ter-soluble compounds. That could be explained by the hydrophilic nature of calcein at
neutral pH in liposomes. Therefore, penetration of calcein across the membrane is very
slow and liposomes could retain a higher amount of originally entrapped marker. In the
case of FITC-dextrans, even slower release in the buffer of pH 4.5 than in the study with
calcein is probably a consequence of steric effects due to the higher molecular mass of
encapsulated compounds.
To be closer to the application of liposomes in humans, an appropriate viscosity of
liposomal preparations is required. This can be achieved by their incorporation in a ve-
hicle suitable for vaginal self-administration. One of the limitations of conventional dos-
age forms in vaginal therapy is the relatively short residence time of the drug at the site
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pH 7.4 (proliposomes) pH 7.4 (PD liposomes)
pH 4.5 (proliposomes) pH 4.5 (PD liposomes)
Fig. 1. In vitro stability of liposomes
with CHL. The values denote the
mean  SD (n = 3).
of application. Because a prolonged retention on the mucous wall is often required for
the desired therapeutic effect, research efforts have been directed to using hydrophilic
polymers with bioadhesive characteristics to improve drug delivery via the vagina (22).
It has already been proven that liposomes are fairly compatible with polymers derived
from crosslinked poly(acrylic acid) polymers (12, 13). Therefore it seemed logical to cho-
ose a gel made of Carbopol 974P NF resin as a vehicle for liposomes incorporation.
In this study, proliposomes with CHL were mixed into 1% Carbopol 974P NF gel
and tested for in vitro release of the entrapped drug. As already described (13, 21), a
method modified by Peschka et al. (14) was applied to follow the release of CHL from
the liposomes incorporated in the gel. The porosity of the 2% agarose matrix allowed in-
tact liposomes and released (free) drug to diffuse through the matrix into the receptor
solution (buffer, pH 4.5 or VFS). The amount of CHL released from the gel was deter-
mined spectrophotometrically, before and after the addition of methanol to the super-
natant over the agarose matrix.
Results presented in Tables II and III and Fig. 2a show a slower release of CHL from
liposomes incorporated in Carbopol gel then from the control gel. After 24 hours of in-
cubation at 37 °C in the buffer, pH 4.5, more than 47% of the originally entrapped CHL
was still retained in the liposomes, in comparison to the control (13%). Slightly lower
values were obtained in VFS (Fig. 2a). The model used to study the release of CHL from
liposomes incorporated in the gel gave valuable information about intact liposomes re-
leased from the gel through the agarose matrix into the receptor media. CHL in intact
liposomes was calculated as the difference between total CHL and free CHL, namely, af-
ter and before addition of methanol to the supernatant over the gel. As presented in Ta-
bles II and III, the amount of diffused intact liposomes was higher in the buffer of pH 4.5
(Table II) than in VFS (Table III), thus indicating a lower stability of liposomes in the
presence of vaginal fluid components. Thus, after 24 hours of incubation in the buffer of
pH 4.5, about 24% of CHL remained in the intact liposomes, while only 12% CHL re-
mained in intact liposomes when experiments were performed in VFS. Statistically lo-
wer release of CHL from liposomes in the gel compared to the control gel was observed
only after 24 h of incubation at 37 °C, both in the buffer of pH 4.5 and in VFS.
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Table II. In vitro release of CHL entrapped in liposomes incorporated in the gel (buffer pH 4.5)






1 9.27 ± 1.15 11.63 ± 1.15 2.36 ± 1.83 9.78 ± 2.68 NS
2 16.43 ± 3.27 23.75 ± 7.22 7.32 ± 4.92 17.83 ± 4.17 NS
4 24.36 ± 3.91 33.55 ± 7.92 9.18 ± 7.51 29.15 ± 7.82 NS
6 30.72 ± 4.70 45.55 ± 11.54 14.83 ± 12.83 36.93 ± 8.71 NS
24 52.76 ± 4.23 76.91 ± 9.01 24.15 ± 10.72 87.12 ± 6.20 S
The values denote the mean ± SD (n = 3).
a Before disruption of liposomes by methanol.
b After disruption of liposomes by methanol.
c Difference between b and a.
d Statistical analysis difference vs. control: NS – not statistically significant difference, S – statistically significant.
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a)
b)
Table III. In vitro release of CHL entrapped in liposomes incorporated in the gel (VFS, pH 4.5)






1 8.85 ± 1.89 14.45 ± 0.83 5.80 ± 3.45 9.78 ±2.68 NS
2 16.88 ± 2.49 20.76 ± 0.40 5.09 ± 1.84 17.83 ± 4.17 NS
4 27.01 ± 1.43 29.39 ± 3.87 2.59 ± 1.92 29.15 ± 7.82 NS
6 35.66 ± 1.05 38.73 ± 0.63 2.64 ± 0.48 36.93 ± 8.71 NS
24 59.75 ± 3.35 71.18 ± 12.99 12.37 ± 8.87 87.12 ± 6.20 S
The values denote the mean ± SD (n = 3).
a Before disruption of liposomes by methanol.
b After disruption of liposomes by methanol.
c Difference between b and a.
d Statistical analysis difference vs. control: NS – not statistically significant difference, S – statistically significant.
Fig. 2. Cumulative release of CHF from pro-
liposomes incorporated in the gel in differ-
ent media. a) The amounts of released drug
were detected in receptor media before ad-
dition of methanol. b) The data are replot-
ted according to the Higuchi equation (23).
The values denote the mean ± SD (n = 3).
When the amount of CHL retained in the gel is plotted against the square root of
time, a linear correlation according to the Higuchi equation (23) is obtained (Fig. 2b),
showing matrix-controlled diffusion of the released drug.
In studies with hydrophilic compounds (13, 21), after 24 hours of incubation in the
buffer of pH 4.5, only 16% of the originally encapsulated calcein, or 12% of FITC-dextran
4400, or 8% of FITC-dextran 21200 were released from the Carbopol gel. Such findings
were expected because of the inverse correlation between the release rate and the mole-
cular mass of the encapsulated marker. Release of CHL from liposomes incorporated in
the gel was much faster probably due to the solubility of the lipophilic drug in acidic
media. Since the gel pH was 5.5 and investigations were performed in media of low pH
(pH 4.5), these results seem to be quite reasonable.
Regarding the physical properties of the vehicle for liposomes incorporation, it has
been confirmed that the Carbopol 974P NH gel offers an adequate pH value and rheo-
logical properties (13). Due to the well-known loss of viscosity caused by sodium ions
(24) from the buffer in which liposomes were made, the original gel was made in the
concentration of 1% (m/m), and after addition of 10% liposomes, suitable viscosity was
achieved (13). In order to provide a stable vehicle for vaginal application in which lipo-
somes are distributed uniformly and their structure is preserved, a storage stability stu-
dy was performed. Liposomal gels with CHL were kept for 4 weeks at 20 °C and 40 °C
(stress testing). During those experiments, the size distribution and the mean diameter
of the incorporated liposomes were determined. Results presented in Fig. 3 demonstrate
the ability of the Carbopol 974P NF gel to preserve the original size distribution of lipo-
somes with CHL. The mean diameter of proliposomes was 325 nm (immediately after
incorporation in a vehicle). After 4 weeks of storage, the mean diameter changed from
325 to 361 nm (at 20 °C) and to 385 nm (at 40 °C) but the distribution remained almost
unchanged. The data show that the percentage of smaller liposomes marginally decre-
ased, while larger liposomes increased in number (Fig. 3).
327



















After 4 weeks (20 °C)
After 4 weeks (40 °C)
Fig. 3. Size distribution of proliposomes in the gel stored for 4 weeks at 20 and 40 °C.
CONCLUSIONS
Proliposome and polyol dilution methods yield similar entrapment efficiency for
CHL. Since better stability of liposomes in vitro is observed with proliposomes, the pro-
liposome method would be the proper choice of the preparation method. Incorporation
of proliposomes in bioadhesive Carbopol gel improved their stability and enabled a sus-
tained release of the drug, confirming the applicability of liposomes containing CHL as
a novel delivery system for the local treatment of bacterial vaginosis.
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S A @ E T A K
Gel s liposomski uklopljenim kloramfenikolom: karakterizacija
i osloba|anje in vitro
@ELJKA PAVELI], NATA[A [KALKO-BASNET I IVAN JAL[ENJAK
Cilj ovog rada bio je priprava i razvoj liposomskog terapijskog sustava s uklopljenim
kloramfenikolom namijenjenog lokalnoj terapiji bakterijskog vaginitisa. Kloramfenikol je
uklopljen u liposome fosfolipidnog sastava fosfatidilkolin/fosfatidilglicerol (molarni om-
jer 9:1), prire|ene dvjema metodama, proliposomskom i metodom razrje|enja poliola.
Obje preparacije su uspore|ene i liposomi su karakterizirani s obzirom na veli~inu ~es-
tica, polidisperznost, te uspje{nost uklapanja. Provedena su ispitivanja stabilnosti lipo-
soma in vitro u medijima koji svojim pH i sastavom opona{aju humanu vaginalnu sluz-
nicu (pufer pH 4.5 i umjetni vaginalni medij). Kako bi se postigla prikladna viskoznost
pripravka i dodatno pove}ala stabilnost liposoma namijenjenih vaginalnoj primjeni, li-
posomi su umije{ani u bioadhezivni gel pripravljen iz karbopola 974P NF. In vitro ispi-
tivanja s liposomima uklopljenima u gel pokazala su produljeno osloba|anje uklopljenog
kloramfenikola. Pritom se ~ak nakon 24 sata inkubacije u umjetnom vaginalnom mediju
vi{e od 40% po~etno uklopljenog kloramfenikola zadr`alo u gelu. Ispitivanja stabilnosti
liposoma u gelu tijekom skladi{tenja potvrdila su povoljan u~inak gela na o~uvanje po-
~etne raspodjele uklopljenih liposoma s obzirom na veli~inu. Ispitivanja provedena u
ovom radu potvr|uju mogu}nost primjene liposoma kao novog terapijskog sustava u
lokalnoj terapiji bakterijskih vaginalnih infekcija.
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